3:49 PM
 | 
Apr 16, 2019
 |  BC Extra  |  Company News

WuXi Biologics to supply CMC and commercial manufacturing for I-Mab

WuXi Biologics expanded its partnership with I-Mab to include biologics process development and clinical and commercial manufacturing of at least six undisclosed programs.

WuXi Biologics Inc. (HKSE:2269) will provide CMC services...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >